Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18396703 | 0.81 | MTOR (0.36) | MAOA | |
| SCHEMBL240100 | 0.81 | KDM4E (0.46) | MAOAALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL29209046 | 0.81 | KDM4E (0.46) | MAOAALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL4706606 | 0.80 | MAOA (0.33) | MAOAALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL239087 | 0.78 | MAOA (0.32) | MAOAALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL238837 | 0.78 | MAOA (0.32) | MAOAALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL241355 | 0.76 | ALDH1A1 (0.32) | MAOAALDH1A1 | |
| SCHEMBL236762 | 0.76 | KDM4E (0.35) | MAOAALDH1A1MAPT | |
| SCHEMBL241891 | 0.76 | ALDH1A1 (0.32) | MAOAALDH1A1 | |
| SCHEMBL22698326 | 0.75 | MAOA (0.35) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549641-A1 | ANTIMICROBIAL 3.1.0 BICYCLIC OXAZOLIDINONE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
| WO-2004033451-A1 | ANTIMICROBIAL [3.1.0] BICYCLIC OXAZOLIDINONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | MAOA 743/4885ALDH1A1 345/4885LMNA 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.